Stockpolly
Search
PTHS · AMEX · Biotechnology

Pelthos Therapeutics (PTHS)

Commercializes topical treatments for molluscum, impetigo, and head lice.

$25.91
Pre-market+0.89 (+3.56%)
At close$25.02(+0.81%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000791116
Cost of revenue00000005455
Gross profit000000025611
422222318171928
Research & development20000010001
212222317161727
Selling & marketing00000005340
General & administrative01222231213130
Other expenses00000001110
Operating income−4−2−2−2−2−2−3−15−12−13−17
0−100000−1−173−6
Interest income00000000000
Interest expense01000001122
Other non-operating income0000000015−50
Income before tax−4−3−2−2−2−2−3−17−29−10−23
Income tax expense00000000−700
Net income from continuing operations−4−3−2−2−2−2−3−16−22−10−23
Net income−4−3−2−2−2−2−3−16−22−10−23
EPS, basic−$6.87−$5.50−$3.07−$2.90−$3.23−$3.20−$5.38−$25.35−$6.87−$3.09−$6.62
EPS, diluted−$6.87−$5.50−$3.07−$2.90−$3.23−$3.20−$5.38−$25.35−$6.87−$3.09−$6.62
Weighted average shares, basic10111111334
Weighted average shares, diluted10111111334
EBITDA−4−2−2−2−2−2−3−15−26−6−16
Depreciation & amortization00000001121
EBIT−4−2−2−2−2−2−3−15−27−8−17